The University of Pennsylvania's Gene Therapy Program will partner with Regeneron to explore whether its two-antibody “cocktail” REGEN-COV2 (casirivimab and imdevimab) can prevent COVID-19 infection when delivered as a nasal spray via AAV vectors, using expertise developed by GTP and its director James M. Wilson, MD, PhD . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge